LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

LeMaitre Vascular reports solid Q4 performance and eyes growth

LeMaitre Vascular's Q4 2022 performance showed growth in sales and income, with strong guidance for 2023.
Despite challenges with gross margin and product line issues, the company is well-positioned for future growth.
Opportunities lie in M&A, sales force expansion, and improving operational efficiency.
Strategic investments have bolstered the company's ability to meet demand and regulatory requirements.

LeMaitre Vascular reports robust Q1 sales and eyes Asia expansion

LeMaitre Vascular delivered strong sales and operating income in Q1 2023, driven by pricing strategies and market expansion efforts.
While facing challenges like rising expenses and competitor risks, the company aims to maintain profitability and drive growth through strategic initiatives.
Opportunities in Asia Pacific expansion and the Aziyo distribution agreement offer avenues for revenue growth and margin improvement.
Overall, LeMaitre's focus on maintaining margins, exploring new markets, and product innovation positions it for continued success in 2023.

LeMaitre Vascular reports robust Q2 sales growth and eyes international expansion

LeMaitre Vascular's Q2 performance reflects strong sales growth, pricing power, and operational efficiency, positioning the company for future success.
While facing margin challenges, the company's diversified product portfolio, international expansion plans, and solid cash position present growth opportunities.
Strategic focus on addressing challenges, optimizing operations, and capitalizing on growth opportunities will be crucial for sustained success and market leadership.

LeMaitre Vascular excels in Q3, eyes growth opportunities ahead

LeMaitre Vascular's Q3 performance was strong, with growth in sales and margins.
The company faces challenges in international markets and sales and marketing dynamics.
Opportunities lie in pricing strategies, product focus, and upcoming product filings.
Overall, LeMaitre Vascular is well-positioned for growth and strategic acquisitions.

LeMaitre Vascular posts strong Q4 results, eyes global expansion opportunities

LeMaitre Vascular's strong performance in Q4 2023 showcases robust sales growth and margin improvement.
While facing challenges such as ongoing impacts from the pandemic and tax rate assumptions, the company is well-positioned for growth.
Strategic initiatives like sales force expansion, APAC expansion, and M&A activities align with opportunities for market penetration and revenue growth.
Guidance for 2024 indicates a focus on operational efficiency and growth strategies to drive continued success.

LeMaitre Vascular excels in Q1 2024, eyes European expansion

Overall, LeMaitre Vascular's Q1 performance showcases strong financial growth, operational improvements, and strategic positioning for future success. The company's focus on expanding its market presence and product approvals sets a positive outlook for continued growth and profitability.

LeMaitre Vascular (LMAT) reports strong Q3 performance and eyes APAC growth

LeMaitre Vascular (LMAT) demonstrated robust sales growth, operational strength, and strategic focus in Q3 2024, positioning itself for continued success. Challenges include pricing strategies and leadership transition, while opportunities exist in sales expansion, regulatory milestones, and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LeMaitre (LMAT) delivered earnings and revenue surprises of 0.00% and 0.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Matches Q1 Earnings Estimates

Shares of LeMaitre Vascular (NASDAQ:LMAT) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 75.00% over the past year to $0.28, which beat the estimate of $0.27.

Recap: LeMaitre Vascular Q1 Earnings

Bull Of The Day: LeMatire Vascular (LMAT)

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LeMaitre Vascular (LMAT) Earnings Expected to Grow: Should You Buy?

BURLINGTON, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2021 financial results on Thursday, April 29, 2021, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce First Quarter 2021 Earnings Results on April 29, 2021

Cantel Medical

Hill-Rom Hlds

Masimo

Cantel (CMD), Hill-Rom (HRC), LeMaitre (LMAT) and Masimo (MASI) can prove to be prudent investment choices in the critical care industry of the MedTech sector.

4 Critical Care Device Stocks to Deflect the COVID-19 Curveball

Abbott Labs

Hologic

IDEXX Laboratories

Here are a few MedTech stocks, ABT, HOLX, HRC, IDXX, LMAT, which have held their ground amid the pandemic and can turn out to be wise investment choices for 2021.

5 MedTech Growth Stocks Gaining Ground in 2021 Amid Pandemic

Bridget Ross brings extensive experience in MedTech development and services; Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms.

Former Johnson & Johnson Executive Joins Advisory Board at Maitri Health Technologies

Assured Guaranty

Anthem

Auburn National Bancorporation

Blackrock Inc

Commerce Bancshares

Cogent Communications Holdings

CME Group

Core-Mark Holding Company

Equity LifeStyle Properties

Franco-Nevada C

Horizon

Healthcare Services Group

Home Depot

International Flavors & Fragrances

Independent Bank

Jack Henry & Associates

Lithia Motors

L3Harris

Lockheed Martin

Main Street Capital

Medtronic

Monro

Altria

Insperity

A weekly summary of dividend activity for Dividend Champions and Contenders. Companies which changed their dividends.

Dividend Champion And Contender Highlights: Week Of March 21

LeMaitre (LMAT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

LeMaitre (LMAT) Stock Jumps 5.2%: Will It Continue to Soar?

LeMaitre Vascular's (LMAT) CEO George LeMaitre on Q4 2020 Results - Earnings Call Transcript

Shares of LeMaitre Vascular (NASDAQ:LMAT) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 47.83% over the past year to $0.34, which beat the estimate of $0.29.

Recap: LeMaitre Vascular Q4 Earnings

BURLINGTON, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2020 results and announced an $0.11/share quarterly dividend.

LeMaitre Q4 2020 Financial Results

AbbVie

Principal Healthcare Innovators Index ETF

Direxion Daily Healthcare Bull 3x Shares

Fidelity MSCI Health Care ETF

First Trust Nasdaq Pharmaceuticals ETF 

First Trust Health Care AlphaDEX Fund

abrdn Healthcare Investors 

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare ETF

John Hancock Multifactor Healthcare ETF

Global X Longevity Thematic ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

ProShares UltraShort Health Care

ProShares Ultra Health Care

Invesco S&P 500 Equal Weight Health Care ETF

abrdn Life Sciences Investors 

Vanguard Health Care ETF

Pacer BioThreat ETF

Health Care Select Sector SPDR Fund

SPDR S&P Pharmaceuticals ETF

The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets.

Healthcare: A Wide Choice Of Large And Well-Established Companies

BURLINGTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in four upcoming investor conferences.

LeMaitre Vascular to Present at Upcoming Investor Conferences

BURLINGTON, Mass., Jan. 27, 2021 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2020 financial results on Thursday, February 25, 2021, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Vascular Will Announce Fourth Quarter 2020 Earnings Results on February 25, 2021

The LeMaitre's corporate health partly depends on how much its sales reps can do to overcome current blocks, and how soon the pandemic ends.

Checking LeMaitre Vascular For Blocked Arteries

LeMaitre has posted a strong quarter compounded by successful acquisition activity YTD, with little OPEX tied into profits in Q3. Management has widened the capital structure to be more debt inclusive, having realised the upside on Artegraft and CardioCel asset returns.

LeMaitre: Widened Capital Structure, Acquisitions Drive Top-Line Growth

Ituran Location & Control

Logitech

Shutterstock

Winnebago

Here are five top-ranked liquid stocks, Winnebago Industries, (WGO), Shutterstock (SSTK), Logitech (LOGI), Ituran Location and Control (ITRN), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.

5 Top-Ranked Liquid Stocks To Bet On For Alluring Returns

Here are four top-ranked liquid stocks, Winnebago Industries (WGO), Shutterstock (SSTK), Logitech (LOGI), and LeMaitre Vascular (LMAT), that investors can snap up for a winning portfolio.

4 Promising Top-Ranked Liquid Stocks to Boost Your Portfolio

LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

3 Reasons Why Growth Investors Shouldn't Overlook LeMaitre (LMAT)

Polen Capital Management recently released its Q3 2020 Investor Letter, a copy of which you can download here. During the third quarter of 2020, the Polen U.S. Small Company Growth Composite Portfolio returned 4.57% gross of fees, while the Russell 2000 Growth Index was up 7.17%. You should check out Polen Capital's top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.

Should You Be Tempted To ‘Sell' LeMaitre Vascular (LMAT) Stock

BURLINGTON, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020, at 12:25 PM ET.

LeMaitre Vascular to Present at the Jefferies Virtual London Healthcare Conference

LeMaitre Vascular, Inc. (LMAT) CEO George LeMaitre on Q3 2020 Results - Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of 76.19% and 13.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Q3 Earnings and Revenues Top Estimates

News for LeMaitre Vascular Stock (LMAT)